Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis
Clinical trial NCT05916365 · COMPLETED
Trial details
- NCT number
- NCT05916365
- Sponsor
- Almirall, S.A.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-23
- Primary completion
- 2026-04-23
- Enrollment
- 174
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.